Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections | Zendy

Sara Alosaimy | Zendy; Sarah C J Jorgensen | Zendy; Abdalhamid M Lagnf | Zendy; Sarah Melvin | Zendy; Ryan P. Mynatt | Zendy; Travis J Carlson | Zendy; Kevin W. Garey | Zendy; David W. Allen | Zendy; Veena Venugopalan | Zendy; Michael P. Veve | Zendy; Vasilios Athans | Zendy; Stephen Saw | Zendy; Christine Yost | Zendy; Susan L. Davis | Zendy; Michael J. Rybak | Zendy

Open Access

Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections

Author(s) -

Sara Alosaimy,

Sarah C J Jorgensen,

Abdalhamid M Lagnf,

Sarah Melvin,

Ryan P. Mynatt,

Travis J Carlson,

Kevin W. Garey,

David W. Allen,

Veena Venugopalan,

Michael P. Veve,

Vasilios Athans,

Stephen Saw,

Christine Yost,

Susan L. Davis,

Michael J. Rybak

Publication year - 2020

Publication title -

open forum infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.546

H-Index - 35

ISSN - 2328-8957

DOI - 10.1093/ofid/ofaa051

Subject(s) - medicine , meropenem , gram , rash , enterobacteriaceae , gram negative bacterial infections , carbapenem , microbiology and biotechnology , antibiotics , antibiotic resistance , bacteria , escherichia coli , biology , biochemistry , genetics , gene

Fourty patients were treated with meropenem-vaborbactam (MEV) for serious Gram-negative bacterial (GNB) infections. Carbapenem-resistant (CRE) comprised 80.0% of all GNB infections. Clinical success occurred in 70.0% of patients. Mortality and recurrence at 30 days were 7.5% and 12.5%, respectively. One patient experienced a probable rash due to MEV.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research